Advanced search
Start date

Impact of the circadian clock on the DNA repair capacity and drug sensitivity of normal and cancer cells: towards chronopersonalized chemotherapy

Grant number: 15/50080-6
Support type:Regular Research Grants
Duration: April 01, 2016 - March 31, 2019
Field of knowledge:Biological Sciences - Genetics
Cooperation agreement: Erasmus Universiteit Rotterdam
Mobility Program: SPRINT - Projetos de pesquisa - Mobilidade
Principal researcher:Carlos Frederico Martins Menck
Grantee:Carlos Frederico Martins Menck
Principal researcher abroad: Gijsbertus Theodorus Johannes van der Horst
Institution abroad: Erasmus University Rotterdam (EUR), Netherlands
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated research grant:14/15982-6 - Consequences of repair deficiencies in damaged genome, AP.TEM


The circadian clock is an internal timing mechanism, orchestrating diurnal variations in behavior, physiology and metabolism, aimed to best prepare us for daily recurring changes in our environment (i,e. the light/dark cycle). Evidence is increasing that uptake, metabolization and detoxification of chemicals is under control of the circadian clock and that, accordingly, the severity of toxic responses can depend on the time-of-day of exposure. Such chronotoxic properties of compounds can be very useful when treating cancer with chemotherapeutic or other anti-cancer agents. Chronomodulated therapy involves protocols in which chemotherapeutic agents are given at a specific moment of the day. The purpose of this project is to make a start with the evaluation of the impact of the circadian system on mechanisms of DNA damage processing (including DNA damage repair and replication of damaged DNAtransletion synthesis), and, as a consequence, the sensitivity of normal and cancer cells to chemotherapeutic compounds_ Ultimately, this knowledge can be used to develop chronomodulated treatment protocols for clinical application (chronopersonalized medicine), aiming at optimizing therapeutic efficacy, and reducing unwanted side effects. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items